Vitamin D and diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 2, 2010, Pages 419-446

  Takiishi, Tatiana ^a   Gysemans, Conny ^a   Bouillon, Roger ^a   Mathieu, Chantal ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cells; Deficiency; Immune system; Type 1 diabetes; Type 2 diabetes; Vitamin D

Indexed keywords

C PEPTIDE; CALCITRIOL; CALCIUM; COLECALCIFEROL; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ERGOCALCIFEROL; GAMMA INTERFERON; HLA DR ANTIGEN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; LEXACALCITOL; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PROTEIN APAL; PROTEIN BSML; PROTEIN TAQL; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLINDNESS; CALCIUM CELL LEVEL; CALCIUM INTAKE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEMENTIA; DENDRITIC CELL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE MODEL; DRUG MEGADOSE; FRACTURE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; GRAFT REJECTION; HEART FAILURE; HIP FRACTURE; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; LIFESTYLE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; STROKE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET B RADIATION; VISUAL IMPAIRMENT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE INTOLERANCE; HUMANS; IMMUNE SYSTEM; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; PANCREATITIS; RATS; RECEPTORS, CALCITRIOL; VITAMIN D; VITAMIN D DEFICIENCY; VITAMIN D-BINDING PROTEIN;

MUS;

EID: 77953932853     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.02.013     Document Type: Review

References (208)

1. IDF diabetes atlas 2009, International Diabetes Federation, Available at:, Accessed November 11, 2009. http://www.diabetesatlas.org/, 4th edition.
2. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002, 113(Suppl 6A):3S-11S.
3. Knip M., Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008, 7(7):550-557.
4. Palomer X., Gonzalez-Clemente J.M., Blanco-Vaca F., et al. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008, 10(3):185-197.
5. Wilkin T.J. Changing perspectives in diabetes: their impact on its classification. Diabetologia 2007, 50(8):1587-1592.
6. Resmini E., Minuto F., Colao A., et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009, 46(2):85-95.
7. Bouillon R., Carmeliet G., Verlinden L., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008, 29(6):726-776.
8. Mathieu C., Gysemans C., Giulietti A., et al. Vitamin D and diabetes. Diabetologia 2005, 48(7):1247-1257.
9. Nyomba B.L., Auwerx J., Bormans V., et al. Pancreatic secretion in man with subclinical vitamin D deficiency. Diabetologia 1986, 29(1):34-38.
10. Harris S.S. Vitamin D in type 1 diabetes prevention. J Nutr 2005, 135(2):323-325.
11. Knip M. Natural course of preclinical type 1 diabetes. Horm Res 2002, 57(Suppl 1):6-11.
12. Barrett J.C., Clayton D.G., Concannon P., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009, 41(6):703-707.
13. Steck A.K., Zhang W., Bugawan T.L., et al. Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR, DQ genotypes?. Diabetes 2009, 58(4):1028-1033.
14. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1A diabetes. N Engl J Med 2009, 360(16):1646-1654.
15. Lopez E.R., Regulla K., Pani M.A., et al. CYP27B1 polymorphisms variants are associated with type 1 diabetes mellitus in Germans. J Steroid Biochem Mol Biol 2004, 89-90(1-5):155-157.
16. Pani M.A., Regulla K., Segni M., et al. Vitamin D 1alpha-hydroxylase (CYP1alpha) polymorphism in Graves' disease, Hashimoto's thyroiditis and type 1 diabetes mellitus. Eur J Endocrinol 2002, 146(6):777-781.
17. Bailey R., Cooper J.D., Zeitels L., et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007, 56(10):2616-2621.
18. Ogunkolade B.W., Boucher B.J., Prahl J.M., et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002, 51(7):2294-2300.
19. van Etten E., Verlinden L., Giulietti A., et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol 2007, 37(2):395-405.
20. Garcia D., Angel B., Carrasco E., et al. VDR polymorphisms influence the immune response in type 1 diabetic children from Santiago, Chile. Diabetes Res Clin Pract 2007, 77(1):134-140.
21. Pociot F., McDermott M.F. Genetics of type 1 diabetes mellitus. Genes Immun 2002, 3(5):235-249.
22. Pani M.A., Knapp M., Donner H., et al. Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 2000, 49(3):504-507.
23. Chang T.J., Lei H.H., Yeh J.I., et al. Vitamin D receptor gene polymorphisms influence susceptibility to type 1 diabetes mellitus in the Taiwanese population. Clin Endocrinol (Oxf) 2000, 52(5):575-580.
24. Guo S.W., Magnuson V.L., Schiller J.J., et al. Meta-analysis of vitamin D receptor polymorphisms and type 1 diabetes: a HuGE review of genetic association studies. Am J Epidemiol 2006, 164(8):711-724.
25. Lemos M.C., Fagulha A., Coutinho E., et al. Lack of association of vitamin D receptor gene polymorphisms with susceptibility to type 1 diabetes mellitus in the Portuguese population. Hum Immunol 2008, 69(2):134-138.
26. Turpeinen H., Hermann R., Vaara S., et al. Vitamin D receptor polymorphisms: no association with type 1 diabetes in the Finnish population. Eur J Endocrinol 2003, 149(6):591-596.
27. Israni N., Goswami R., Kumar A., et al. Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India. PLoS One 2009, 4(12):e8023.
28. Karvonen M., Viik-Kajander M., Moltchanova E., et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000, 23(10):1516-1526.
29. Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes Epidemiology Research International Group. Diabetes 1988, 37(8):1113-1119.
30. Sloka S., Grant M., Newhook L.A. The geospatial relation between UV solar radiation and type 1 diabetes in Newfoundland. Acta Diabetol 2010, 47(1):73-78.
31. Staples J.A., Ponsonby A.L., Lim L.L., et al. Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 2003, 111(4):518-523.
32. Cantorna M.T., Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004, 229(11):1136-1142.
33. Mohr S.B., Garland C.F., Gorham E.D., et al. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 2008, 51(8):1391-1398.
34. Karvonen M., Jantti V., Muntoni S., et al. Comparison of the seasonal pattern in the clinical onset of IDDM in Finland and Sardinia. Diabetes Care 1998, 21(7):1101-1109.
35. Neu A., Kehrer M., Hub R., et al. Incidence of IDDM in German children aged 0-14 years. A 6-year population-based study (1987-1993). Diabetes Care 1997, 20(4):530-533.
36. Kahn H.S., Morgan T.M., Case L.D., et al. Association of type 1 diabetes with month of birth among U.S. youth: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009, 32(11):2010-2015.
37. Bouillon R., Verstuyf A., Branisteanu D., et al. Verh K Acad Geneeskd Belg 1995, 57(5):371-377. [in Dutch].
38. 3 receptors in human leukocytes. Science 1983, 221(4616):1181-1183.
39. 3 receptor in the immune system. Arch Biochem Biophys 2000, 374(2):334-338.
40. Dong X., Lutz W., Schroeder T.M., et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci U S A 2005, 102(44):16007-16012.
41. 3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 2006, 83(7):1299-1309.
42. Guery J.C., Adorini L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol 1995, 154(2):536-544.
43. Schwartz R.H. A cell culture model for T lymphocyte clonal anergy. Science 1990, 248(4961):1349-1356.
44. Griffin M.D., Lutz W.H., Phan V.A., et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000, 270(3):701-708.
45. van Halteren A.G., van Etten E., de Jong E.C., et al. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D3. Diabetes 2002, 51(7):2119-2125.
46. 3 alters the profile of bone marrow-derived dendritic cells of NOD mice. Ann N Y Acad Sci 2004, 1037:186-192.
47. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164(5):2405-2411.
48. 3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 2004, 23(3):233-239.
49. Ferreira G.B., van Etten E., Lage K., et al. Proteome analysis demonstrates profound alterations in human dendritic cell nature by TX527, an analogue of vitamin D. Proteomics 2009, 9(14):3752-3764.
50. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 2003, 987:258-261.
51. 3. Blood 2005, 106(10):3490-3497.
52. 3 inhibits antigen-induced T cell activation. J Immunol 1984, 133(4):1748-1754.
53. 3 (calcitriol). J Clin Invest 1984, 74(4):1451-1455.
54. 3. Immunology 1986, 59(4):479-484.
55. 3 regulates proliferation of activated T-lymphocyte subsets. Life Sci 1985, 37(1):95-101.
56. 3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987, 79(6):1659-1664.
57. 3 has a direct effect on naïve CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167(9):4974-4980.
58. 3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 1999, 84(10):3739-3744.
59. 3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51(5):1367-1374.
60. Ghoreishi M., Bach P., Obst J., et al. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J Immunol 2009, 182(10):6071-6078.
61. Hewison M., Gacad M.A., Lemire J., et al. Vitamin D as a cytokine and hematopoetic factor. Rev Endocr Metab Disord 2001, 2(2):217-227.
62. Baeke F., van Etten E., Gysemans C., et al. Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 2008, 29(6):376-387.
63. 3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009, 183(9):5458-5467.
64. 3 on human B cell differentiation. J Immunol 2007, 179(3):1634-1647.
65. 3 inhibits proliferative response of T- and B-lymphocytes in a serum-free culture. Int J Immunopharmacol 1987, 9(6):719-723.
66. 3 derivatives on type-1 cellular immunity. Biomed Res 2006, 27(1):1-9.
67. 3: basic concepts. J Steroid Biochem Mol Biol 2005, 97(1-2):93-101.
68. Sia C. Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus. Rev Diabet Stud 2005, 2(4):182-186.
69. Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus?. Nutr Res Rev 2005, 18(2):175-182.
70. Eizirik D.L., Cardozo A.K., Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29(1):42-61.
71. 3 reduces MHC antigen expression on pancreatic beta-cells in vitro. Transplant Proc 1997, 29(4):2156-2157.
72. 3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 2002, 143(12):4809-4819.
73. 3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006, 11(2):151-159.
74. 3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005, 146(4):1956-1964.
75. Mathieu C., Waer M., Laureys J., et al. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994, 37(6):552-558.
76. 3 prevents insulitis in NOD mice. Diabetes 1992, 41(11):1491-1495.
77. 3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. J Autoimmun 2005, 24(4):281-289.
78. 3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clin Exp Immunol 1998, 112(2):181-187.
79. 3, KH1060. Endocrinology 1995, 136(3):866-872.
80. Del Pino-Montes J., Benito G.E., Fernandez-Salazar M.P., et al. Calcitriol improves streptozotocin-induced diabetes and recovers bone mineral density in diabetic rats. Calcif Tissue Int 2004, 75(6):526-532.
81. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352(25):2598-2608.
82. 3 analog and cyclosporine. Transplantation 1998, 65(9):1225-1232.
83. Mathieu C., Van Etten E., Gysemans C., et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 2001, 16(11):2057-2065.
84. Gysemans C., Van Etten E., Overbergh L., et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 2002, 128(2):213-220.
85. Zeitz U., Weber K., Soegiarto D.W., et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003, 17(3):509-511.
86. Gysemans C., van Etten E., Overbergh L., et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 2008, 57(1):269-275.
87. Hypponen E., Laara E., Reunanen A., et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358(9292):1500-1503.
88. Stene L.C., Ulriksen J., Magnus P., et al. Use of cod liver oil during pregnancy associated with lower risk of type I diabetes in the offspring. Diabetologia 2000, 43(9):1093-1098.
89. Stene L.C., Joner G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003, 78(6):1128-1134.
90. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999, 42(1):51-54.
91. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93(6):512-517.
92. Fronczak C.M., Baron A.E., Chase H.P., et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003, 26(12):3237-3242.
93. Wicklow B.A., Taback S.P. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann N Y Acad Sci 2006, 1079:310-312.
94. Pitocco D., Crino A., Di Stasio E., et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 2006, 23(8):920-923.
95. Pozzilli P., Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001, 24(8):1460-1467.
96. 3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009, 25(5):411-416.
97. Pittas A.G., Harris S.S., Eliades M., et al. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94(3):827-832.
98. Guillausseau P.J., Meas T., Virally M., et al. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 2008, 34(Suppl 2):S43-S48.
99. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414(6865):782-787.
100. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br J Nutr 2003, 89(5):552-572.
101. Scragg R. Vitamin D and type 2 diabetes: are we ready for a prevention trial?. Diabetes 2008, 57(10):2565-2566.
102. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes care 2004, 27(12):2813-2818.
103. Chiu K.C., Chu A., Go V.L., et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004, 79(5):820-825.
104. Ford E.S., Ajani U.A., McGuire L.C., et al. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005, 28(5):1228-1230.
105. Forouhi N.G., Luan J., Hennings S., et al. Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med 2007, 24(2):200-207.
106. 3 on insulin secretion. Diabetes 1981, 30(5):382-386.
107. Boucher B.J. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'?. Br J Nutr 1998, 79(4):315-327.
108. 3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes care 2006, 29(3):722-724.
109. Giulietti A., van Etten E., Overbergh L., et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007, 77(1):47-57.
110. DeFronzo R.A., Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32(Suppl 2):S157-S163.
111. Boucher B.J. Does vitamin D status contribute to caveolin-1-mediated insulin sensitivity in skeletal muscle?. Diabetologia 2009, 52(10):2240. author reply 2241-3.
112. Oh Y.S., Khil L.Y., Cho K.A., et al. A potential role for skeletal muscle caveolin-1 as an insulin sensitivity modulator in ageing-dependent non-obese type 2 diabetes: studies in a new mouse model. Diabetologia 2008, 51(6):1025-1034.
113. 3 in vivo and in vitro. Mol Endocrinol 2004, 18(11):2660-2671.
114. Malecki M.T. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005, 68(Suppl 1):S10-21.
115. Cooke N.E., Haddad J.G. Vitamin D binding protein (Gc-globulin). Endocr Rev 1989, 10(3):294-307.
116. Hirai M., Suzuki S., Hinokio Y., et al. Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. J Clin Endocrinol Metab 2000, 85(5):1951-1953.
117. Hirai M., Suzuki S., Hinokio Y., et al. Group specific component protein genotype is associated with NIDDM in Japan. Diabetologia 1998, 41(6):742-743.
118. Klupa T., Malecki M., Hanna L., et al. Amino acid variants of the vitamin D-binding protein and risk of diabetes in white Americans of European origin. Eur J Endocrinol 1999, 141(5):490-493.
119. Malecki M.T., Klupa T., Wanic K., et al. Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 2002, 57(2):99-104.
120. Sinotte M., Diorio C., Berube S., et al. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009, 89(2):634-640.
121. Uitterlinden A.G., Fang Y., van Meurs J.B., et al. Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol 2004, 89-90(1-5):187-193.
122. Uitterlinden A.G., Fang Y., Van Meurs J.B., et al. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338(2):143-156.
123. Valdivielso J.M., Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006, 371(1-2):1-12.
124. Oh J.Y., Barrett-Connor E. Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. Metabolism 2002, 51(3):356-359.
125. Ortlepp J.R., Metrikat J., Albrecht M., et al. The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 2003, 20(6):451-454.
126. Filus A., Trzmiel A., Kuliczkowska-Plaksej J., et al. Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. Aging Male 2008, 11(3):134-139.
127. Ye W.Z., Reis A.F., Dubois-Laforgue D., et al. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. Eur J Endocrinol 2001, 145(2):181-186.
128. Dilmec F., Uzer E., Akkafa F., et al. Detection of VDR gene ApaI and TaqI polymorphisms in patients with type 2 diabetes mellitus using PCR-RFLP method in a Turkish population. J Diabetes Complications 2009, [Epub ahead of print].
129. Bid H.K., Konwar R., Aggarwal C.G., et al. Vitamin D receptor (FokI, BsmI and TaqI) gene polymorphisms and type 2 diabetes mellitus: a North Indian study. Indian J Med Sci 2009, 63(5):187-194.
130. Malecki M.T., Frey J., Moczulski D., et al. Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 2003, 111(8):505-509.
131. Speer G., Cseh K., Winkler G., et al. Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. Eur J Cancer 2001, 37(12):1463-1468.
132. Norman A.W., Frankel J.B., Heldt A.M., et al. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980, 209(4458):823-825.
133. Chertow B.S., Sivitz W.I., Baranetsky N.G., et al. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983, 113(4):1511-1518.
134. 3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986, 119(1):84-90.
135. Kumar P.D., Rajaratnam K. Renal diseases in diabetes mellitus. J Indian Med Assoc 1997, 95(7):426-428.
136. Kadowaki T., Miyake Y., Hagura R., et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984, 26(1):44-49.
137. Chertow B.S., Sivitz W.I., Baranetsky N.G., et al. Islet insulin release and net calcium retention in vitro in vitamin D-deficient rats. Diabetes 1986, 35(7):771-775.
138. 3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology 1987, 120(4):1490-1497.
139. 3 on pancreatic B and D cell function. Life Sci 1983, 33(18):1779-1786.
140. 3 on insulin production by neonatal rat islets. Biochem Biophys Res Commun 1989, 164(1):413-418.
141. 3-mediated rapid stimulation of intestinal calcium transport, (transcaltachia). Endocrinology 1990, 127(1):39-45.
142. 3 on pancreatic islet insulin release via the cyclic AMP pathway in the rat. Br J Pharmacol 1997, 121(4):751-758.
143. 3-1alpha-hydroxylase knockout mice. FASEB J 2002, 16(11):1398-1406.
144. Milner R.D., Hales C.N. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia 1967, 3(1):47-49.
145. Hou J.C., Min L., Pessin J.E. Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm 2009, 80:473-506.
146. Rhodes C.J., Alarcon C. What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 1994, 43(4):511-517.
147. Hitman G.A., Mannan N., McDermott M.F., et al. Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998, 47(4):688-690.
148. 2+ regulates calmodulin binding to IQ motifs in IRS-1. Biochemistry 1996, 35(49):15883-15889.
149. Li Z., Joyal J.L., Sacks D.B. Binding of IRS proteins to calmodulin is enhanced in insulin resistance. Biochemistry 2000, 39(17):5089-5096.
150. McCarty M.F., Thomas C.A. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 2003, 61(5-6):535-542.
151. 3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 1994, 134(4):1602-1610.
152. Huotari M.A., Palgi J., Otonkoski T. Growth factor-mediated proliferation and differentiation of insulin-producing INS-1 and RINm5F cells: identification of betacellulin as a novel beta-cell mitogen. Endocrinology 1998, 139(4):1494-1499.
153. Sergeev I.N., Rhoten W.B. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 1995, 136(7):2852-2861.
154. 2+ concentration in pancreatic beta-cells through nongenomic signal transduction. Endocrinology 1999, 140(10):4706-4712.
155. Larsen C.M., Faulenbach M., Vaag A., et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32(9):1663-1668.
156. Chang-Quan H., Bi-Rong D., Ping H., et al. Insulin resistance, renal injury, renal 1-alpha hydroxylase, and bone homeostasis in aged obese rats. Arch Med Res 2008, 39(4):380-387.
157. 3 on the glucose and calcium metabolism in genetic obese mice. Res Commun Chem Pathol Pharmacol 1981, 33(1):155-161.
158. Anderson R.L., Rowling M.J. Renal 25-hydroxycholecalciferol reabsorption is modulated in a type II diabetic rat model. FASEB J 2009, 23:736. [1_meeting abstracts], 1.
159. de Souza Santos R., Vianna L.M. Effect of cholecalciferol supplementation on blood glucose in an experimental model of type 2 diabetes mellitus in spontaneously hypertensive rats and Wistar rats. Clin Chim Acta 2005, 358(1-2):146-150.
160. Ceylan-Isik A., Hunkar T., Asan E., et al. Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats. J Pharm Pharmacol 2007, 59(12):1629-1641.
161. Silva E.G., Vianna L.M., Okuyama P., et al. Effect of treatment with cholecalciferol on the membrane potential and contractility of aortae from spontaneously hypertensive rats. Br J Pharmacol 1996, 118(6):1367-1370.
162. Nilas L., Christiansen C. Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes 1984, 8(5):407-411.
163. 3 on insulin secretion in diabetes mellitus. Bone Miner 1986, 1(3):187-192.
164. Gedik O., Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986, 29(3):142-145.
165. Ljunghall S., Lind L., Lithell H., et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance-a prospective randomized double-blind study. Acta Med Scand 1987, 222(4):361-367.
166. Kumar S., Davies M., Zakaria Y., et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994, 70(824):440-443.
167. Boucher B.J., Mannan N., Noonan K., et al. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995, 38(10):1239-1245.
168. Allegra V., Luisetto G., Mengozzi G., et al. Glucose-induced insulin secretion in uremia: role of 1 alpha,25(HO)2-vitamin D3. Nephron 1994, 68(1):41-47.
169. Orwoll E., Riddle M., Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994, 59(5):1083-1087.
170. Fliser D., Stefanski A., Franek E., et al. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest 1997, 27(7):629-633.
171. Taylor A.V., Wise P.H. Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J 1998, 74(872):365-366.
172. 3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003, 57(4):258-261.
173. Pittas A.G., Dawson-Hughes B., Li T., et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes care 2006, 29(3):650-656.
174. Pittas A.G., Harris S.S., Stark P.C., et al. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes care 2007, 30(4):980-986.
175. de Boer I.H., Tinker L.F., Connelly S., et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008, 31(4):701-707.
176. 3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009, 26(1):19-27.
177. Pittas A.G., Lau J., Hu F.B., et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007, 92(6):2017-2029.
178. Knekt P., Laaksonen M., Mattila C., et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008, 19(5):666-671.
179. von Hurst P.R., Stonehouse W., Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 2009, 103(4):549-555.
180. Avenell A., Cook J.A., MacLennan G.S., et al. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2009, 38(5):606-609.
181. Kazemi B., Seyed N., Moslemi E., et al. Insulin receptor gene mutations in Iranian patients with type II diabetes mellitus. Iran Biomed J 2009, 13(3):161-168.
182. Holmes V.A., Barnes M.S., Alexander H.D., et al. Vitamin D deficiency and insufficiency in pregnant women: a longitudinal study. Br J Nutr 2009, 102(6):876-881.
183. 3 deficiency and insulin resistance in pregnancy. Diabetes Metab Res Rev 2008, 24(1):27-32.
184. Zhang C., Qiu C., Hu F.B., et al. Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. PLoS One 2008, 3(11):e3753.
185. Lapillonne A. Vitamin D deficiency during pregnancy may impair maternal and fetal outcomes. Med Hypotheses 2010, 74(1):71-75.
186. Rudnicki P.M., Molsted-Pedersen L. Effect of 1,25-dihydroxycholecalciferol on glucose metabolism in gestational diabetes mellitus. Diabetologia 1997, 40(1):40-44.
187. Zhang Y., Deb D.K., Kong J., et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009, 297(3):F791-F801.
188. Chonchol M., Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 2007, 71(2):134-139.
189. Diaz V.A., Mainous A.G., Carek P.J., et al. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 2009, 22(5):521-527.
190. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72(8):1004-1013.
191. 3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000, 33(1):47-51.
192. Parekh N., Chappell R.J., Millen A.E., et al. Association between vitamin D and age-related macular degeneration in the Third National Health and Nutrition Examination Survey, 1988 through 1994. Arch Ophthalmol 2007, 125(5):661-669.
193. Gouni-Berthold I., Krone W., Berthold H.K. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 2009, 7(3):414-422.
194. Judd S.E., Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci 2009, 338(1):40-44.
195. Bouillon R. Vitamin D as potential baseline therapy for blood pressure control. Am J Hypertens 2009, 22(8):816.
196. Schmitz K.J., Skinner H.G., Bautista L.E., et al. Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens 2009, 22(8):867-870.
197. Pilz S., Marz W., Wellnitz B., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008, 93(10):3927-3935.
198. de Boer I.H., Kestenbaum B., Shoben A.B., et al. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009, 20(8):1805-1812.
199. Tishkoff D.X., Nibbelink K.A., Holmberg K.H., et al. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008, 149(2):558-564.
200. Wu-Wong J.R., Nakane M., Ma J., et al. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem 2007, 100(6):1395-1405.
201. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167(16):1730-1737.
202. Lee P., Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med 2008, 168(7):771-772.
203. Xu W., Qiu C., Gatz M., et al. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009, 58(1):71-77.
204. Miazgowski T., Krzyzanowska-Swiniarska B., Ogonowski J., et al. Does type 2 diabetes predispose to osteoporotic bone fractures?. Endokrynol Pol 2008, 59(3):224-229.
205. Zinman B., Haffner S.M., Herman W.H., et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95(1):134-142.
206. 3 receptor in chick skeletal muscle myoblasts. Biochem Biophys Res Commun 1985, 128(1):305-311.
207. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169(6):551-561.
208. Boonen S., Lips P., Bouillon R., et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007, 92(4):1415-1423.